Myasthenia Gravis (MG) is caused by autoantibodies targeting the neuromuscular junction, leading to fatigable muscle weakness. New targeted therapies include:
- Efgartigimod (Vyvgart®) – neonatal Fc receptor (FcRn) blockade
- Ravulizumab (Ultomiris®) – complement inhibition
- Rozanolixizumab (Rystiggo®) – subcutaneous FcRn inhibitor
These therapies allow for rapid symptom control while minimizing long-term immunosuppression.